An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)-Reference-Cited by-同舟云学术

An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)

Published:2021-11-29 Issue: Volume: Page:1-20
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Chu Cilong¹,Rao Zixuan¹,Pan Qingshan¹,Zhu Wufu¹

Affiliation:

1. Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, Jiangxi, China

Funder

Foundation of China

China

Evaluation

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2022.2008356

Reference67 articles.

1. Targeting the c-MET signaling pathway for cancer therapy

2. Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors

3. Biological significance and targeting of c-Met tyrosine kinase receptor in cancer

4. Design, synthesis, and biological evaluation of 4-phenoxyquinoline derivatives as potent c-Met kinase inhibitor

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: An updated review;Bioorganic & Medicinal Chemistry;2024-09

2. Computational Simulation Study of Potential Inhibition of c‐Met Kinase Receptor by Phenoxy pyridine Derivatives: Based on QSAR, Molecular Docking, Molecular Dynamics;Chemistry & Biodiversity;2024-08-30

3. A Bispecific Chimeric Aptamer Design Platform Based on c‐MET Aptamer with a Replaceable Redundant Region;ChemBioChem;2024-08-13

4. Rational Design of PARP1/c-Met Dual Inhibitors for Overcoming PARP1 Inhibitor Resistance Induced by c-Met Overexpression;Journal of Medicinal Chemistry;2024-03-13

5. 4‐{3‐[(Pyridin‐4‐ylmethyl)amino]‐[1,2,4]triazolo[4,3‐b][1,2,4]triazin‐6‐yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator;Archiv der Pharmazie;2024-03-05